. 2021 Nov 14;27(42):7387–7401. doi: 10.3748/wjg.v27.i42.7387

Table 3.

Subgroup analysis of overall survival, progression-free survival and 5-year survival

Subgroups		OS (mo)	PFS (mo)	5-yr survival (%)
Subgroups		Median/n, range/%	Median/n, range/%	5-yr survival (%)
Treatment	F-IGRT (n = 27)	21.0, 0-87	12.0, 0-74	47.2
Treatment	S-IGRT (n = 4)	17.0, 3-49	18.0, 2-32	0.0
Intent	Curative (n = 23)	22.0, 0-87	14.0, 0-74	51.5
Intent	Palliative (n = 8)	8.0, 0-79	4, 0-13	30.0
Location	Oesophageal (n = 22)	18, 0-87	13, 0-74	42.8
	SCC (n = 16)	20, 1-87	14, 1-74	62.0
	AC (n = 6)	10, 0-54	7, 0-19	0.0
	Gastric (n=9)	25, 0-79	13, 0-53	55.6

F-IGRT: Fiducial-based image-guided radiotherapy; S-IGRT: Standard image-guided radiotherapy; SCC: Squamous cell carcinoma; AC: Adenocarcinoma; OS: Overall survival; PFS: Progression-free survival.